SHARE:   Share to Facebook Share to Twitter Share to Linked In Share via Email  

Back To Search Results

S24 - MS Therapeutics and Clinical Research I

Event Time: Tuesday April 25, 2017 3:30 pm to 5:30 pm
Topic(s): MS and CNS Inflammatory Disease
Director(s):
Description: A group of abstracts covering a similar topic presented in an oral format. Presentations are eight minutes in length with four minutes of question and answer. Each session concludes with 25 minutes of a discussant bringing additional context to one or more of the abstracts.
Completion Message:
CME Credits: 2
Core Competencies:

Program Speakers - Tentative

Start/End Time Title Faculty
5:10 PM - 5:30 PM Discussion James Stankiewicz MD 

Disclosures

Speaker Disclosure
James M. Stankiewicz, MD consulting Teva Neuroscience; consulting Novartis, consulting Genzyme, consulting Biogen Idec, consulting Genentech, consulting consulting Bayer, consulting Mallinkrodt.

Abstract Presenters

Start Time Pub. Title Presenter
3:30 PM 001 Dimethyl fumarate treatment produces alterations in lipid metabolism that are linked to occurrence of lymphopenia Pavan Bhargava, MD
Disclosure:
Dr. Bhargava has nothing to disclose.

3:42 PM 002 Depletion of CD8+ cells in patients with multiple sclerosis on dimethyl fumarate and its association with shingles Ursela Siddiqui, MD
Disclosure:
Dr. Siddiqui has nothing to disclose.

3:54 PM 003 Ofatumumab Differs from Rituximab by Effectively Targeting Lymph Node B cells and Achieving Faster Post-treatment Repletion Paul Smith
Disclosure:
I am an employee of Novartis Pharma AG, Switzerland. Author is an employee of Novartis Pharma AG, Switzerland. Author is an employee of Novartis Pharma AG, Switzerland. Author is an employee of Novartis Pharma AG, Switzerland.

4:06 PM 004 Ambulation Assistive Device Training Prevents Falls, Increases Device Satisfaction and May Decrease Sitting and Increase Walking in MS: A Randomized-Controlled Pilot Study Andrea Hildebrand
Disclosure:
Dr. Hildebrand has nothing to disclose.

4:18 PM 005 Improvements in Clinical Outcomes With Alemtuzumab in Treatment-Naive Patients With Active Relapsing-Remitting Multiple Sclerosis Are Durable Over 6 Years in the Absence of Continuous Treatment (CARE-MS I) Barry Singer, MD
Disclosure:
Dr. Singer has received personal compensation for activities with Acorda, Bayer, Biogen, EMD Serono, Genentech, Novartis, Sanofi Genzyme, and Teva CNS as a speaker and/or consultant. Dr. Singer has received research support from Acorda, Biogen, MedImmune, Novartis, Roche, and Sanofi Genzyme.

4:30 PM 006 Alemtuzumab Provides Durable Efficacy Over 6 Years in Patients With Active Relapsing-Remitting Multiple Sclerosis and an Inadequate Response to Prior Therapy in the Absence of Continuous Treatment (CARE-MS II) Edward J Fox, MD, PhD, FAAN
Disclosure:
Dr. Fox has received personal compensation for activities with Acorda, Bayer, Biogen, EMD Serono, Genentech, Novartis, Roche, Sanofi Genzyme, and Teva Neuroscience. Dr. Fox has received research support from Acorda, Biogen, Chugai, EMD Serono, Novartis, Opexa, Roche, Sanofi Genzyme, and Teva Neuroscience.

4:42 PM 007 Fitness to drive in persons with MS and cognitive impairment: a pilot study Sarah Anne Morrow, MD, MSC,FRCPC
Disclosure:
Dr. Morrow has received honoraria for speaking, consulting, and advisory board participation from Biogen Idec, EMD Serono, Genzyme, Novartis, and Roche. . Dr. Morrow has acted as site principal investigator for clinical trials for Biogen Idec, Genzyme, Novartis, and Roche. She has received investigator initiated study funds from Biogen Idec, Genzyme and Novartis..

4:54 PM 008 Efficacy and Safety of Ozanimod: Results From the 2-Year Blinded Extension of RADIANCE, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial in Relapsing Multiple Sclerosis Jeffrey Cohen, MD
Disclosure:
Dr. Cohen has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Adams, Celgene. Dr. Cohen has received personal compensation in an editorial capacity for Mult Scler J - ETC.

Register Now

Related Courses

Saturday April 21, 2018

9:30 AM-11:30 AM
C11 Treatment of Pediatric Multiple Sclerosis in the Current Era Brenda Banwell MD, FAAN

Sunday April 22, 2018

7:00 AM-9:00 AM
C33 Multiple Sclerosis in the Trenches: Controversy and Consensus in Clinical Decision-Making Aaron Miller MD, FAAN
3:30 PM-5:30 PM
C57 Spanish: Update on MS Therapy Lilyana Amezcua MD

Tuesday April 24, 2018

7:00 AM-9:00 AM
C97 Multiple Sclerosis Overview I: Clinical Pearls John Corboy MD, FAAN
1:00 PM-3:00 PM
C107 Multiple Sclerosis Overview II: Clinical Advances Scott Newsome DO, FAAN
3:30 PM-5:30 PM
C121 Multiple Sclerosis Overview III: Basic and Translational Science Michael Racke MD

Wednesday April 25, 2018

7:00 AM-9:00 AM
C135 Multiple Sclerosis Therapy: Disease-modifying Treatment I David Jones MD
9:15 AM-11:30 AM
PL5 Frontiers in Neuroscience Plenary Session
1:00 PM-3:00 PM
C146 Multiple Sclerosis Therapy: Disease-modifying Treatment II John Rose MD, FAAN
3:30 PM-5:30 PM
C161 Multiple Sclerosis Therapy: Symptom Management Jonathan Carter MD

Thursday April 26, 2018

7:00 AM-9:00 AM
C174 Clinical Pearls in Autoimmune Neurology: Real World Cases Stacey Clardy MD, PhD
1:00 PM-3:00 PM
N5 Neuroscience in the Clinic: Treatment of Progressive Multiple Sclerosis Eric Klawiter MD,
Ellen Mowry MD, FAAN

Friday April 27, 2018

1:00 PM-3:00 PM
C223 Neuromyelitis Optica Spectrum Disorders Dean Wingerchuk MD, FAAN

MEMBER LOG IN

Forgot Password?